ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

被引：0

作者：

Cho, B. C. ^{[1
]}

Piotrowska, Z. ^{[2
]}

Le, X. ^{[3
]}

Goldberg, S. B. ^{[4
]}

Goldman, J. ^{[5
]}

De langen, A. ^{[6
]}

Okamoto, I. ^{[7
]}

Smith, P. ^{[8
]}

Mensi, I. ^{[8
]}

Maidment, J. ^{[8
]}

Hartmaier, R. ^{[9
]}

Li, M. ^{[10
]}

Doughton, G. ^{[8
]}

Patel, G. ^{[8
]}

Pease, J. ^{[8
]}

Szekeres, P. ^{[8
]}

Riess, J. ^{[11
]}

Yu, H. ^{[12
]}

机构：

[1] Severance Hosp, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[2] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, AL USA

[4] Yale Sch Med, New Haven, CT USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[6] Netherlands Canc Inst, Amsterdam, Netherlands

[7] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan

[8] Astrazeneca, Cambridge, England

[9] Astrazeneca, Translat Med Oncol Res & Early Dev, Waltham, MA USA

[10] Astrazeneca, Precis Med, Gaithersburg, MD USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

osimertinib; non-small cell lung cancer; resistance;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P76.27

引用

页码：S598 / S598

页数：1